Cyxone

Cyxone is a clinical-stage biotechnology company focused on developing a new generation of disease-modifying therapies for autoimmune and autoinflammatory diseases. The company's portfolio is built on two primary technological pillars: first-in-class small molecules and cyclotide-based drugs. These therapies are designed to inhibit key processes in the body's immune cells, such as pro-inflammatory cytokines, to treat conditions like rheumatoid arthritis (RA) and multiple sclerosis (MS). The company's lead assets include Rabeximod, an oral small molecule in Phase 2 development for RA, and T20K, a cyclotide-based candidate for MS. Cyxone aims to address significant unmet medical needs by providing safer, more effective, and more convenient treatment options compared to current biologics and immunosuppressants. The company operates with a lean virtual model, leveraging partnerships with academic institutions and contract research organizations (CROs) to advance its pipeline.